Ark Therapeutics: Viral Specialist Seeking A Niche
Edison | Sep 24, 2012 02:35AM ET
Ark Therapeutics’ (AKT.L) transition from a therapeutics development company to a contract development and manufacturing organisation (CDMO) is complete. The near-term investment case therefore rests on its ability to secure contracts for its viral-based cGMP manufacturing facility in Kuopio, Finland. The expertise, capabilities and potential of the Kuopio facility, core to winning over new clients, is firmly established and Ark has a pipeline of 20 potential contracts under discussion with partners ranging from large pharma to academic institutions.
Viral specialist seeking a niche
Ark is offering its manufacturing, research and development services to all aspects of viral-based product development, including viral-mediated gene therapy, oncolytic viruses and vaccines. Ark estimates a £500m global potential market for outsourced, viral-based product manufacturing services, the bulk of the value coming from pre-clinical development work. This indicates a significant opportunity when compared to Ark’s £3.6m fixed annual manufacturing overheads.
Strategy starting to deliver
Recently signed manufacturing deals – with an undisclosed European gene therapy company and a non-binding letter of intent with EMD Millipore – show that Ark is starting to deliver on its new business model. Manufacturing contracts with PsiOxus and Glasgow University signed last year are progressing successfully and extensions are under discussion.
Partners sought for pipeline candidates
Ark is aiming for £2m in annual savings from a cost-reduction initiative, which includes a significantly reduced headcount in its London office and ceasing further investment in its own pipeline of early clinical-stage VEGF-D gene therapy candidates and a pre-clinical NRP-1 antagonist programme (partners sought to fund further development).
Valuation: Revised rNPV of £15m
We have removed Ark’s pipeline candidates from our valuation model and revised our estimates for the manufacturing business, giving an rNPV of £15m (previously £22m), which compares favourably with Ark’s £2.1m EV. For 2012 and 2013 we forecast manufacturing revenues of £2.5m and £6.5m respectively, but any revenue shortfall would put pressure on Ark’s £4.9m current cash reserve. Securing multiple, financially substantial contracts could stimulate a re-rating of the shares and our valuation.
Get The News You Want
To Read the Entire Report Please Click on the pdf File Below.
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.